• LAST PRICE
    1.0100
  • TODAY'S CHANGE (%)
    Trending Down-0.0300 (-2.8846%)
  • Bid / Lots
    0.9490/ 1
  • Ask / Lots
    1.1500/ 2
  • Open / Previous Close
    1.0400 / 1.0400
  • Day Range
    Low 0.9953
    High 1.1316
  • 52 Week Range
    Low 0.5999
    High 9.0000
  • Volume
    42,560
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.04
TimeVolumePAVM
09:32 ET12181.04
09:43 ET26550.9953
09:52 ET10001.1316
10:06 ET1001.0001
10:48 ET5001.05
11:08 ET6001.04
11:13 ET4001.02
11:15 ET1001.01
11:26 ET1021.03
11:36 ET3001.0343
11:38 ET1501.0201
11:44 ET1001.0238
11:49 ET4001.03
11:51 ET3001.01
11:54 ET59601.0275
12:23 ET6791.03
12:39 ET4001.065
12:52 ET1791.0501
01:03 ET11001.051
01:48 ET21391.045
02:08 ET51971.03
02:44 ET90001.01
02:51 ET9321.0113
03:16 ET1001.0399
03:21 ET1341.04
03:23 ET29951.0102
03:34 ET16001.0399
03:36 ET1001.035
03:50 ET2001.01
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPAVM
PAVmed Inc
10.9M
-0.1x
---
United StatesLPTI
Longport Inc
20.0
0.0x
---
United StatesAKSY
Aksys Ltd
30.0
0.0x
---
United StatesBIEL
BioElectronics Corp
2.5M
-7.5x
---
United StatesADMT
ADM Tronics Unlimited Inc
4.4M
-7.5x
---
United StatesOHCS
Optimus Healthcare Services Inc
2.3M
-0.1x
---
As of 2024-07-19

Company Information

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.

Contact Information

Headquarters
360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
Phone
212-949-4319
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Lishan Aklog
President, Chief Financial Officer
Dennis Mcgrath
Independent Vice Chairman of the Board
Michael Glennon
Chief Operating Officer, Executive Vice President
Shaun O'Neil
Chief Technology Officer, Chief Compliance Officer
Brian Deguzman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$10.9M
Revenue (TTM)
$3.0M
Shares Outstanding
9.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.69
EPS
$-9.08
Book Value
$-6.28
P/E Ratio
-0.1x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
---
Operating Margin
-2,256.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.